Option chain shows key data for FibroBiologics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for FibroBiologics.

FibroBiologics (NASDAQ:FBLG) Stock, Option Chain

FibroBiologics

FibroBiologics, Inc. - Common Stock

FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.

Stock market analysts

News

Initiation

Markets

Analyst Ratings

Trading Ideas

CARM

FBLG

IVVD

This NANO Nuclear Energy Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Wednesday

Image22

Pre-Market Outlook

Movers

BBCP

BMEA

DOCU

FTEL

REPL

Vail Resorts Posts Downbeat Q3 Results, Joins Concrete Pumping, DocuSign And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

xr:d:DAFtH5xd8iU:2,j:4016486423666345323,t:23083115

Intraday Update

AMBC

ASNS

BGXX

BNED

CLEU

CMPS

CVAC

DLTR

DOYU

FRES

GDHG

GWRE

HLTH

JDZG

JEWL

MITQ

MLGO

MMYT

MNMD

MPLN

MYND

NDRA

NVAX

NVVE

OLLI

SFIX

SGRP

SILO

SOBR

SYTA

THMO

UMAC

UNFI

VLCN

VRNT

VSTE

WKME

XTIA

Why Lands&#39; End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

FibroBiologics Inc

Press Releases

FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024

Health Care

FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology

Earnings

FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Legal

FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics

FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly

Financing

FibroBiologics Announces $25 Million Financing

D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing

FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing

FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates

FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic

AlloVir

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

CytomX Therapeutics

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Dyadic International, Inc. - Common Stock

Dyadic International

Fortress Biotech

ImmuCell

Immix Biopharma

Immuneering Corporation - Class A Common Stock

Immuneering

Kala Bio

Kezar Life Sciences

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

Lantern Pharma

MAIA Biotechnology

OKYO Pharma

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Rein Therapeutics

Repare Therapeutics

Serina Therapeutics

Spero Therapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Xilio Therapeutics

D. Boral Capital

HC Wainwright & Co.

Rodman & Renshaw

EF Hutton

Maxim Group

Comments

FibroBiologics

FibroBiologics (FBLG) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga